The drug API Innovation Center (APIIC) is proud to announce our collaborative efforts to establish a cutting-edge research and development lab at the University of Missouri-St. Louis (UMSL) campus. This lab will be dedicated to advancing new continuous flow routes of synthesis (RoS) for the process development stage of small molecule active pharmaceutical ingredients (APIs). This initiative underscores our commitment to bolstering national health security by reshoring domestic API production and addressing critical drug shortages.

By leveraging UMSL’s renowned expertise in organic and inorganic chemistry, biochemistry, materials science, and drug development, we aim to accelerate the transition of small-molecule APIs, with no U.S. source, from traditional batch processes to new continuous flow processes using advanced manufacturing technology. This lab, equipped with specialized technologies and equipment, will serve as a center for innovative API research and development. 

The API Innovation Center-UMSL collaboration exemplifies our shared vision to establish the St. Louis region as a national hub for API reshoring. By investing in research, education, and industry partnerships, we are paving the way for a more resilient and secure drug supply chain while contributing to Missouri’s economic growth. Stay tuned for updates as we pioneer new pathways in pharmaceutical development and contribute to a more secure drug supply chain for Americans.

The API Innovation Center is supported by the state of Missouri through the Advanced Manufacturing Resiliency Grant awarded by the Missouri Technology Corporation. The U.S. Department of Commerce’s Economic Development Administration (EDA) awarded a Build Back Better grant to help supply the new laboratory.